Bioatla to participate in the jmp securities hematology and oncology summit

San diego, nov. 30, 2023 (globe newswire) -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics for the treatment of solid tumors, today announced that the company's management will participate in a fireside chat and scheduled one-on-one investor meetings at the jmp securities hematology and oncology summit, to be held virtually december 5–6, 2023.
BCAB Ratings Summary
BCAB Quant Ranking